Citations (91)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (14)
Xiaoqin Zhu, Jia Zhu, Feifei Sun, Zijun Zhen, Dalei Zhou, Suying Lu, Junting Huang, Yi Que, Lian Zhang, Ruiqing Cai, Juan Wang & Yizhuo Zhang. (2021) Influence of UGT1A1 *6/*28 Polymorphisms on Irinotecan-Related Toxicity and Survival in Pediatric Patients with Relapsed/Refractory Solid Tumors Treated with the VIT Regimen. Pharmacogenomics and Personalized Medicine 14, pages 369-377.
Read now
Read now
Yang Li, Jinjin Xu, Chunxia Xu, Zifei Qin, Shishi Li, Liufang Hu, Zhihong Yao, Frank J. Gonzalez & Xinsheng Yao. (2020) Metabolism and disposition of corylifol A from Psoralea corylifolia: metabolite mapping, isozyme contribution, species differences and identification of efflux transporters for corylifol A-O-glucuronide in HeLa1A1 cells. Xenobiotica 50:8, pages 997-1008.
Read now
Read now
Yang-Liu Xia, Tong-Yi Dou, Xia Lv & Guang-Bo Ge. (2019) In vitro characterization of the glucuronidation pathways of licochalcone A mediated by human UDP-glucuronosyltransferases. Xenobiotica 49:6, pages 671-677.
Read now
Read now
Li Wang, Xiaodan Hong, Zhihong Yao, Yi Dai, Guoping Zhao, Zifei Qin, Baojian Wu, Frank J. Gonzalez & Xinsheng Yao. (2018) Glucuronidation of icaritin by human liver microsomes, human intestine microsomes and expressed UDP-glucuronosyltransferase enzymes: identification of UGT1A3, 1A9 and 2B7 as the main contributing enzymes. Xenobiotica 48:4, pages 357-367.
Read now
Read now
Guangyi Yang, Shufan Ge, Rashim Singh, Sumit Basu, Katherine Shatzer, Ming Zen, Jiong Liu, Yifan Tu, Chenning Zhang, Jinbao Wei, Jian Shi, Lijun Zhu, Zhongqiu Liu, Yuan Wang, Song Gao & Ming Hu. (2017) Glucuronidation: driving factors and their impact on glucuronide disposition. Drug Metabolism Reviews 49:2, pages 105-138.
Read now
Read now
Danyi Lu, Zhiguo Ma, Tianpeng Zhang, Xingwang Zhang & Baojian Wu. (2016) Metabolism of the anthelmintic drug niclosamide by cytochrome P450 enzymes and UDP-glucuronosyltransferases: metabolite elucidation and main contributions from CYP1A2 and UGT1A1. Xenobiotica 46:1, pages 1-13.
Read now
Read now
Chen Yang, Ying Liu, Wen-qi Xi, Chen-fei Zhou, Jin-ling Jiang, Tao Ma, Zheng-bao Ye, Jun Zhang & Zheng-gang Zhu. (2015) Relationship between UGT1A1*6/*28 polymorphisms and severe toxicities in Chinese patients with pancreatic or biliary tract cancer treated with irinotecan-containing regimens. Drug Design, Development and Therapy 9, pages 3677-3683.
Read now
Read now
Hua Sun, Xiaotong Zhou & Baojian Wu. (2015) Accurate identification of UDP-glucuronosyltransferase 1A1 (UGT1A1) inhibitors using UGT1A1-overexpressing HeLa cells. Xenobiotica 45:11, pages 945-953.
Read now
Read now
Hua Sun, Huan Wang, Hongming Liu, Xingwang Zhang & Baojian Wu. (2014) Glucuronidation of capsaicin by liver microsomes and expressed UGT enzymes: reaction kinetics, contribution of individual enzymes and marked species differences. Expert Opinion on Drug Metabolism & Toxicology 10:10, pages 1325-1336.
Read now
Read now
Antonio Gonzalez, Jesse Stombaugh, Catherine Lozupone, Peter J. Turnbaugh, Jeffrey I. Gordon & Rob Knight. (2011) The mind-body-microbial continuum. Dialogues in Clinical Neuroscience 13:1, pages 55-62.
Read now
Read now
Upendra A Argikar, Otito F Iwuchukwu & Swati Nagar. (2008) Update on tools for evaluation of uridine diphosphoglucuronosyltransferase polymorphisms. Expert Opinion on Drug Metabolism & Toxicology 4:7, pages 879-894.
Read now
Read now
Guochun Liao, Xun Zhang, David J. Clark & Gary Peltz. (2008) A Genomic “Roadmap” to “Better” Drugs. Drug Metabolism Reviews 40:2, pages 225-239.
Read now
Read now
Hongjian Zhang, Carl D Davis, Michael W Sinz & A David Rodrigues. (2007) Cytochrome P450 reaction-phenotyping: an industrial perspective. Expert Opinion on Drug Metabolism & Toxicology 3:5, pages 667-687.
Read now
Read now
R. Petkova, S. Chakarov & V. Ganev. (2007) Genetic Bases for Predisposition to Common Multifactorial Disease in Man. Part II. Biotechnology & Biotechnological Equipment 21:4, pages 385-392.
Read now
Read now
Articles from other publishers (77)
Stavros Bashiardes & Christina Christodoulou. (2024) Orally Administered Drugs and Their Complicated Relationship with Our Gastrointestinal Tract. Microorganisms 12:2, pages 242.
Crossref
Crossref
Zhou Chen, Defeng Guan, Zhengfeng Wang, Xin Li, Shi Dong, Junjun Huang & Wence Zhou. (2023) Microbiota in cancer: molecular mechanisms and therapeutic interventions. MedComm 4:6.
Crossref
Crossref
Mihir B. Doshi, Namgyu Lee, Tenzin Tseyang, Olga Ponomarova, Hira Lal Goel, Meghan Spears, Rui Li, Lihua Julie Zhu, Christopher Ashwood, Karl Simin, Cholsoon Jang, Arthur M. Mercurio, Albertha J. M. Walhout, Jessica B. Spinelli & Dohoon Kim. (2023) Disruption of sugar nucleotide clearance is a therapeutic vulnerability of cancer cells. Nature 623:7987, pages 625-632.
Crossref
Crossref
Sandra Kannampuzha & Abilash Valsala Gopalakrishnan. (2023) Cancer chemoresistance and its mechanisms: Associated molecular factors and its regulatory role. Medical Oncology 40:9.
Crossref
Crossref
Xin-Fang Zhai, Jing-Jing Fan, Yang Yi, Meng Zhang, Xia Yuan, Xue Qiao, Lei Liang & Min Ye. (2023) Collaborative modification strategy to develop a highly selective fluorescent probe for human UDP-glucuronosyltransferase 1A10. Chemical Engineering Journal 463, pages 142382.
Crossref
Crossref
Saurav Howlader, Min-Jung Kim, M. Rasheduzzaman Jony, Nguyen Phuoc Long, Yong-Soon Cho, Dong-Hyun Kim & Jae-Gook Shin. (2022)
Characterization of Clofazimine Metabolism in Human Liver Microsomal Incubation
In Vitro
. Antimicrobial Agents and Chemotherapy 66:10.
Crossref
Crossref
Choong-kun Lee, Hong Jae Chon, Woo Sun Kwon, Hyo-Jeong Ban, Sang Cheol Kim, Hyunwook Kim, Hei-Cheul Jeung, Jimyung Chung & Sun Young Rha. (2022) The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients. Genomics & Informatics 20:3, pages e29.
Crossref
Crossref
Hsiang-Lin Tsai, Po-Jung Chen, Yen-Cheng Chen, Ching-Chun Li, Tsung-Kun Chang, Wei-Chih Su, Tzu-Chieh Yin, Ching-Wen Huang & Jaw-Yuan Wang. (2022)
Irinotecan dose reduction in metastatic colorectal cancer patients with homozygous
UGT1A1*28
polymorphism: a single-center case series
. Journal of International Medical Research 50:7, pages 030006052211106.
Crossref
Crossref
Nick Lung-Ngai Ting, Harry Cheuk-Hay Lau & Jun Yu. (2022) Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes. Gut 71:7, pages 1412-1425.
Crossref
Crossref
Bao Guo, Xiaoyan Xu, Miaomiao Shao, Xu Yang, Gaofei He, Kangwei Qi, Jianxin Gu & Lan Wang. (2022) UDP-glucose 6-dehydrogenase lessens sorafenib sensitivity via modulating unfolded protein response. Biochemical and Biophysical Research Communications 613, pages 207-213.
Crossref
Crossref
Ying Zhao, Xin Wang, Yi Liu, Hao-Yu Wang & Jin Xiang. (2022) The effects of estrogen on targeted cancer therapy drugs. Pharmacological Research 177, pages 106131.
Crossref
Crossref
Ryosuke Negoro, Naoki Yamada, Keita Watanabe, Yusuke Kono & Takuya Fujita. (2021) Generation of Caco-2 cells stably expressing CYP3A4·POR·UGT1A1 and CYP3A4·POR·UGT1A1*6 using a PITCh system. Archives of Toxicology 96:2, pages 499-510.
Crossref
Crossref
Prasat Kittakoop. 2021. Human Microbiome. Human Microbiome.
Chalirmporn Atasilp, Phichai Chansriwong, Ekaphop Sirachainan, Thanyanan Reungwetwattana, Suwannee Sirilerttrakul, Monpat Chamnanphon, Apichaya Puangpetch & Chonlaphat Sukasem. (2020) Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy. Scientific Reports 10:1.
Crossref
Crossref
Kimberly Lapham, Jian Lin, Jonathan Novak, Christine Orozco, Mark Niosi, Li Di, Theunis C. Goosen, Sangwoo Ryu, Keith Riccardi, Heather Eng, Kimberly O. Cameron & Amit S. Kalgutkar. (2018)
6-Chloro-5-[4-(1-Hydroxycyclobutyl)Phenyl]-1
H
-Indole-3-Carboxylic Acid is a Highly Selective Substrate for Glucuronidation by UGT1A1, Relative to
β
-Estradiol
. Drug Metabolism and Disposition 46:12, pages 1836-1846.
Crossref
Crossref
M Vukovic, N Radlovic, Z Lekovic, K Vucicevic, N Maric, N Kotur, V Gasic, M Ugrin, M Stojiljkovic, L Dokmanovic, B Zukic & S Pavlovic. (2018)
UGT1A1
(TA)
n
promoter genotype: Diagnostic and population pharmacogenetic marker in Serbia
. Balkan Journal of Medical Genetics 21:1, pages 59-68.
Crossref
Crossref
Jinjin Xu, Mengsen Li, Zhihong Yao, Yezi Zhang, Shishi Li, Liufang Hu, Zifei Qin, Frank J. Gonzalez & Xinsheng Yao. (2018) In vitrometabolic mapping of neobavaisoflavone in human cytochromes P450 and UDP-glucuronosyltransferase enzymes by ultra high-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 158, pages 351-360.
Crossref
Crossref
Sabine Tejpar, Pu Yan, Hubert Piessevaux, Daniel Dietrich, Peter Brauchli, Dirk Klingbiel, Roberto Fiocca, Mauro Delorenzi, Fred Bosman & Arnaud D. Roth. (2018) Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial. European Journal of Cancer 99, pages 66-77.
Crossref
Crossref
Zifei Qin, Shishi Li, Zhihong Yao, Xiaodan Hong, Jinjin Xu, Pei Lin, Guoping Zhao, Frank J. Gonzalez & Xinsheng Yao. (2018) Metabolic profiling of corylin in vivo and in vitro. Journal of Pharmaceutical and Biomedical Analysis 155, pages 157-168.
Crossref
Crossref
Jon C. Cook, Hong Wu, Michael D. Aleo & Karissa Adkins. (2018) Principles of precision medicine and its application in toxicology. The Journal of Toxicological Sciences 43:10, pages 565-577.
Crossref
Crossref
Zifei Qin, Shishi Li, Zhihong Yao, Xiaodan Hong, Baojian Wu, Kristopher W. Krausz, Frank J. Gonzalez, Hao Gao & Xinsheng Yao. (2018) Chemical inhibition and stable knock-down of efflux transporters leads to reduced glucuronidation of wushanicaritin in UGT1A1-overexpressing HeLa cells: the role of breast cancer resistance protein (BCRP) and multidrug resistance-associated proteins (MRPs) in the excretion of glucuronides. Food & Function 9:3, pages 1410-1423.
Crossref
Crossref
Ann K Daly. (2017) Pharmacogenetics: a general review on progress to date. British Medical Bulletin, pages 1-15.
Crossref
Crossref
Xiaodan Hong, Yuanru Zheng, Zifei Qin, Baojian Wu, Yi Dai, Hao Gao, Zhihong Yao, Frank Gonzalez & Xinsheng Yao. (2017) In Vitro Glucuronidation of Wushanicaritin by Liver Microsomes, Intestine Microsomes and Expressed Human UDP-Glucuronosyltransferase Enzymes. International Journal of Molecular Sciences 18:9, pages 1983.
Crossref
Crossref
Matthew C. B. Tsilimigras, Anthony Fodor & Christian Jobin. (2017) Carcinogenesis and therapeutics: the microbiota perspective. Nature Microbiology 2:3.
Crossref
Crossref
Zhihong Yao, Shishi Li, Zifei Qin, Xiaodan Hong, Yi Dai, Baojian Wu, Wencai Ye, Frank J. Gonzalez & Xinsheng Yao. (2017)
Characterization of human UDP-glucuronosyltransferases responsible for glucuronidation and inhibition of norbakuchinic acid, a primary metabolite of hepatotoxicity and nephrotoxicity component bakuchiol in
Psoralea corylifolia
L.
. RSC Advances 7:83, pages 52661-52671.
Crossref
Crossref
Aharon Nachshon, Hanifa J. Abu-Toamih Atamni, Yael Steuerman, Roa'a Sheikh-Hamed, Alexandra Dorman, Richard Mott, Juliane C. Dohm, Hans Lehrach, Marc Sultan, Ron Shamir, Sascha Sauer, Heinz Himmelbauer, Fuad A. Iraqi & Irit Gat-Viks. (2016) Dissecting the Effect of Genetic Variation on the Hepatic Expression of Drug Disposition Genes across the Collaborative Cross Mouse Strains. Frontiers in Genetics 7.
Crossref
Crossref
Hong Xin, Xiao-Yi Qi, Jing-Jing Wu, Xin-Xin Wang, Yan Li, James Y. Hong, Wei He, Wei Xu, Guang-Bo Ge & Ling Yang. (2016) Assessment of the inhibition potential of Licochalcone A against human UDP-glucuronosyltransferases. Food and Chemical Toxicology 90, pages 112-122.
Crossref
Crossref
Zofia Mazerska, Anna Mróz, Monika Pawłowska & Ewa Augustin. (2016) The role of glucuronidation in drug resistance. Pharmacology & Therapeutics 159, pages 35-55.
Crossref
Crossref
Hua Sun, Xiaotong Zhou, Xingwang Zhang & Baojian Wu. (2015) Decreased Expression of Multidrug Resistance-Associated Protein 4 (MRP4/ABCC4) Leads to Reduced Glucuronidation of Flavonoids in UGT1A1-Overexpressing HeLa Cells: The Role of Futile Recycling. Journal of Agricultural and Food Chemistry 63:26, pages 6001-6008.
Crossref
Crossref
Hua Sun, Zhiguo Ma, Danyi Lu & Baojian Wu. (2015) Regio- and Isoform-Specific Glucuronidation of Psoralidin: Evaluation of 3-O-Glucuronidation as a Functional Marker for UGT1A9. Journal of Pharmaceutical Sciences 104:7, pages 2369-2377.
Crossref
Crossref
Xingwang Zhang, Dong Dong, Huailing Wang, Zhiguo Ma, Yifei Wang & Baojian Wu. (2015) Stable Knock-down of Efflux Transporters Leads to Reduced Glucuronidation in UGT1A1-Overexpressing HeLa Cells: The Evidence for Glucuronidation-Transport Interplay. Molecular Pharmaceutics 12:4, pages 1268-1278.
Crossref
Crossref
Zhufeng Wu, Hongming Liu & Baojian Wu. (2015) Regioselective glucuronidation of gingerols by human liver microsomes and expressed UDP-glucuronosyltransferase enzymes: reaction kinetics and activity correlation analyses for UGT1A9 and UGT2B7. Journal of Pharmacy and Pharmacology 67:4, pages 583-596.
Crossref
Crossref
STEFAN BRENNER, JULIANE RIHA, BENEDIKT GIESSRIGL, THERESIA THALHAMMER, MICHAEL GRUSCH, GEORG KRUPITZA, BRUNO STIEGER & WALTER JÄGER. (2015) The effect of organic anion-transporting polypeptides 1B1, 1B3 and 2B1 on the antitumor activity of flavopiridol in breast cancer cells. International Journal of Oncology 46:1, pages 324-332.
Crossref
Crossref
Eduardo de la Torre-Escudero, Ricardo Pérez–Sánchez, Raúl Manzano-Román & Ana Oleaga. (2015) Schistosome infections induce significant changes in the host biliary proteome. Journal of Proteomics 114, pages 71-82.
Crossref
Crossref
Hua Sun, Tianpeng Zhang, Zhufeng Wu & Baojian Wu. (2015) Warfarin is an Effective Modifier of Multiple UDP-Glucuronosyltransferase Enzymes: Evaluation of its Potential to Alter the Pharmacokinetics of Zidovudine. Journal of Pharmaceutical Sciences 104:1, pages 244-256.
Crossref
Crossref
Hongming Liu, Zhufeng Wu, Zhiguo Ma & Baojian Wu. (2014) Glucuronidation of macelignan by human liver microsomes and expressed UGT enzymes: identification of UGT1A1 and 2B7 as the main contributing enzymes. Biopharmaceutics & Drug Disposition 35:9, pages 513-524.
Crossref
Crossref
Gregory A. Plotnikoff. (2014) Three Measurable and Modifiable Enteric Microbial Biotransformations Relevant to Cancer Prevention and Treatment. Global Advances in Health and Medicine 3:3, pages 33-43.
Crossref
Crossref
Douglas F. Dluzen, Dongxiao Sun, Anna C. Salzberg, Nate Jones, Ryan T. Bushey, Gavin P. Robertson & Philip Lazarus. (2014) Regulation of UDP-Glucuronosyltransferase 1A1 Expression and Activity by MicroRNA 491-3p. Journal of Pharmacology and Experimental Therapeutics 348:3, pages 465-477.
Crossref
Crossref
M. S. Reimers, E. C. M. Zeestraten, P. J. K. Kuppen, G. J. Liefers & C. J. H. van de Velde. (2013) Biomarkers in precision therapy in colorectal cancer. Gastroenterology Report 1:3, pages 166-183.
Crossref
Crossref
Adam B. Roberts, Bret D. Wallace, Madhu Kumar Venkatesh, Sridhar Mani & Matthew R. Redinbo. (2013)
Molecular Insights into Microbial
β
-Glucuronidase Inhibition to Abrogate CPT-11 Toxicity
. Molecular Pharmacology 84:2, pages 208-217.
Crossref
Crossref
K Reece & W Figg. 2013. Handbook of Therapeutic Biomarkers in Cancer. Handbook of Therapeutic Biomarkers in Cancer
353
368
.
Mitsuhiro Nishihara, Yuto Hiura, Naohiro Kawaguchi, Junzo Takahashi & Satoru Asahi. (2013) UDP-glucuronosyltransferase 2B15 (UGT2B15) Is the Major Enzyme Responsible for Sipoglitazar Glucuronidation in Humans: Retrospective Identification of the UGT Isoform by In Vitro Analysis and the Effect of UGT2B15*2 Mutation. Drug Metabolism and Pharmacokinetics 28:6, pages 475-484.
Crossref
Crossref
Yuuka Miyake, Kei Mayumi, Hideto Jinno, Toshiko Tanaka-Kagawa, Shizuo Narimatsu & Nobumitsu Hanioka. (2013) cDNA Cloning and Functional Analysis of Minipig Uridine Diphosphate-Glucuronosyltransferase 1A1. Biological and Pharmaceutical Bulletin 36:3, pages 452-461.
Crossref
Crossref
Syed Ahmad, Mark A. Hughes, Li-An Yeh & John E. Scott. (2012) Potential Repurposing of Known Drugs as Potent Bacterial β-Glucuronidase Inhibitors. SLAS Discovery 17:7, pages 957-965.
Crossref
Crossref
M. J. Lamas, G. Duran, E. Balboa, B. Bernardez, S. Candamio, Y. Vidal, A. Mosquera, J. M. Giraldez, R. Lopez, A. Carracedo & F. Barros. (2012) The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens. Cancer Chemotherapy and Pharmacology 69:6, pages 1591-1599.
Crossref
Crossref
Wei Tang, Yi-Ping Fu, Jonine D. Figueroa, Núria Malats, Montserrat Garcia-Closas, Nilanjan Chatterjee, Manolis Kogevinas, Dalsu Baris, Michael Thun, Jennifer L. Hall, Immaculata De Vivo, Demetrius Albanes, Patricia Porter-Gill, Mark P. Purdue, Laurie Burdett, Luyang Liu, Amy Hutchinson, Timothy Myers, Adonina Tardón, Consol Serra, Alfredo Carrato, Reina Garcia-Closas, Josep Lloreta, Alison Johnson, Molly Schwenn, Margaret R. Karagas, Alan Schned, Amanda Black, Eric J. Jacobs, W. Ryan Diver, Susan M. Gapstur, Jarmo Virtamo, David J. Hunter, Joseph F. FraumeniJrJr, Stephen J. Chanock, Debra T. Silverman, Nathaniel Rothman & Ludmila Prokunina-Olsson. (2012) Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer. Human Molecular Genetics 21:8, pages 1918-1930.
Crossref
Crossref
Ann K. Daly. 2012. Current Concepts in Drug Metabolism and Toxicology. Current Concepts in Drug Metabolism and Toxicology
137
167
.
Shogo J. Miyagi & Abby C. Collier. (2011) The Development of UDP-Glucuronosyltransferases 1A1 and 1A6 in the Pediatric Liver. Drug Metabolism and Disposition 39:5, pages 912-919.
Crossref
Crossref
M. Cristina de Almagro, Elisabet Selga, Rémi Thibaut, Cinta Porte, Véronique Noé & Carlos J. Ciudad. (2011) UDP-glucuronosyltransferase 1A6 overexpression in breast cancer cells resistant to methotrexate. Biochemical Pharmacology 81:1, pages 60-70.
Crossref
Crossref
Anand G. PatelScott H. Kaufmann. (2010) Targeting Bacteria to Improve Cancer Therapy. Science 330:6005, pages 766-767.
Crossref
Crossref
Bret D. WallaceHongwei WangKimberly T. LaneJohn E. ScottJillian OransJa Seol KooMadhukumar VenkateshChristian JobinLi-An YehSridhar ManiMatthew R. Redinbo. (2010) Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme. Science 330:6005, pages 831-835.
Crossref
Crossref
Wenjun Ni, Jia Ji, Zunyan Dai, Audrey Papp, Amy J. Johnson, Sunjoo Ahn, Katherine L. Farley, Thomas S. Lin, James T. Dalton, Xiaobai Li, David Jarjoura, John C. Byrd, Wolfgang Sadee, Michael R. Grever & Mitch A. Phelps. (2010) Flavopiridol Pharmacogenetics: Clinical and Functional Evidence for the Role of SLCO1B1/OATP1B1 in Flavopiridol Disposition. PLoS ONE 5:11, pages e13792.
Crossref
Crossref
Ann K. Daly. (2010) Pharmacogenetics and human genetic polymorphisms. Biochemical Journal 429:3, pages 435-449.
Crossref
Crossref
F H Shabaruddin, R A Elliott, J W Valle, W G Newman & K Payne. (2010) Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. British Journal of Cancer 103:3, pages 315-323.
Crossref
Crossref
Hongliang Cai, Nghia Nguyen, Vincent Peterkin, Young-Sun Yang, Kathy Hotz, Deirdre Beaton La Placa, Shujuan Chen, Robert H. Tukey & Jeffrey C. Stevens. (2010)
A Humanized
UGT1
Mouse Model Expressing the
UGT1A1
*
28
Allele for Assessing Drug Clearance by UGT1A1-Dependent Glucuronidation
. Drug Metabolism and Disposition 38:5, pages 879-886.
Crossref
Crossref
Lilian G. Yengi. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
23
.
M.T. Pletcher, J.C. Cook & M.S. Tassinari. 2010. Comprehensive Toxicology. Comprehensive Toxicology
145
161
.
Shu-Feng Zhou. 2010. Supportive Cancer Care with Chinese Medicine. Supportive Cancer Care with Chinese Medicine
293
340
.
Linos P. R. Vandekerckhove, Frauke Christ, Zeger Debyser, Andrew Owen, David Back, Arnout Voet, Jonathan Schapiro & Dirk Vogelaers. 2009. Antiviral Research. Antiviral Research
71
96
.
Magang Shou & Anthony Y. H. Lu. (2009) Antibodies as a Probe in Cytochrome P450 Research. Drug Metabolism and Disposition 37:5, pages 925-931.
Crossref
Crossref
Lilian G. Yengi. 2009. Drug Metabolism Handbook. Drug Metabolism Handbook
65
87
.
Christoph Schulz, Volker Heinemann, Andreas Schalhorn, Nikolas Moosmann, Thomas Zwingers, Stefan Boeck, Clemens Giessen & Hans-Joachim Stemmler. (2009) UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. World Journal of Gastroenterology 15:40, pages 5058.
Crossref
Crossref
ROBERT E. PETRAS & WENDY L. FRANKEL. 2009. Modern Surgical Pathology. Modern Surgical Pathology
755
836
.
Stefanie D. Krämer & Bernard Testa. (2008) The Biochemistry of Drug Metabolism – An Introduction. Chemistry & Biodiversity 5:12, pages 2465-2578.
Crossref
Crossref
Dinemarie Kweekel, Henk-Jan Guchelaar & Hans Gelderblom. (2008) Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treatment Reviews 34:7, pages 656-669.
Crossref
Crossref
John F. Deeken, Rebecca Slack & John L. Marshall. (2008) Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics. Cancer 113:7, pages 1502-1510.
Crossref
Crossref
E. Mrozek, J. Kolesar, D. Young, J. Allen, M. Villalona-Calero & C.L. Shapiro. (2008) Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC). Annals of Oncology 19:8, pages 1417-1422.
Crossref
Crossref
A Ruzzo, F Graziano, F Loupakis, D Santini, V Catalano, R Bisonni, R Ficarelli, A Fontana, F Andreoni, A Falcone, E Canestrari, G Tonini, D Mari, P Lippe, F Pizzagalli, G Schiavon, P Alessandroni, L Giustini, P Maltese, E Testa, E T Menichetti & M Magnani. (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. The Pharmacogenomics Journal 8:4, pages 278-288.
Crossref
Crossref
Joanna Maudlin Pangilinan, Gazala N. Khan & Mark M. Zalupski. (2008) Irinotecan pharmacogenetics: an overview for the community oncologist. Community Oncology 5:2, pages 99-114.
Crossref
Crossref
Nick Orr & Stephen Chanock. 2008.
1
32
.
Ann K. Daly. 2008. Pharmacogenomics and Personalized Medicine. Pharmacogenomics and Personalized Medicine
109
120
.
Donglu Zhang, Duxi Zhang, Dan Cui, Janice Gambardella, Li Ma, Anthony Barros, Lifei Wang, Yunlin Fu, Sandhya Rahematpura, Julia Nielsen, Michael Donegan, Hongjian Zhang & W. Griffith Humphreys. (2007)
Characterization of the UDP Glucuronosyltransferase Activity of Human Liver Microsomes Genotyped for the
UGT1A1*28
Polymorphism
. Drug Metabolism and Disposition 35:12, pages 2270-2280.
Crossref
Crossref
Yingying Guo, Peng Lu, Erin Farrell, Xun Zhang, Paul Weller, Mario Monshouwer, Jianmei Wang, Guochun Liao, Zhaomei Zhang, Steven Hu, John Allard, Steve Shafer, Jonathan Usuka & Gary Peltz. (2007)
In silico
and
in vitro
pharmacogenetic analysis in mice
. Proceedings of the National Academy of Sciences 104:45, pages 17735-17740.
Crossref
Crossref
Hongjian Zhang, Carl D Davis, Michael W Sinz & A David Rodrigues. (2007) Cytochrome P450 reaction-phenotyping: an industrial perspective. Expert Opinion on Drug Metabolism & Toxicology 3:5, pages 667-687.
Crossref
Crossref
Michael H. Court. (2013) A Pharmacogenomics Primer. The Journal of Clinical Pharmacology 47:9, pages 1087-1103.
Crossref
Crossref
Clinton F. Stewart, John C. Panetta, Melinda A. O'Shaughnessy, Stacy L. Throm, Charles H. Fraga, Thandranese Owens, Tiebin Liu, Catherine Billups, Carlos Rodriguez-Galindo, Amar Gajjar, Wayne L. Furman & Lisa M. McGregor. (2007)
UGT1A1
Promoter Genotype Correlates With SN-38 Pharmacokinetics, but Not Severe Toxicity in Patients Receiving Low-Dose Irinotecan
. Journal of Clinical Oncology 25:18, pages 2594-2600.
Crossref
Crossref
O.V. TrubetskoyM. FinelM. KurkelaM. FitzgeraldN.R. PetersF.M. HoffmanV.S. Trubetskoy. (2007) High Throughput Screening Assay for UDP-Glucuronosyltransferase 1A1 Glucuronidation Profiling. ASSAY and Drug Development Technologies 5:3, pages 343-354.
Crossref
Crossref